Article Text
DTB select
EMA suspends licence for ulipristal acetate for uterine fibroids
Abstract
Every month, DTB scans sources of information on treatments, disease management and other healthcare topics for key items to bring to our readers’ attention and help them keep up to date. To do this, we produce succinct, contextualised summaries of the information concerned.
- Health Care Quality, Access, and Evaluation
- Primary Health Care
Statistics from Altmetric.com
Footnotes
Overview of: Medicines and Healthcare products Regulatory Agency. Esmya (ulipristal acetate): suspension of the licence due to risk of serious liver injury. Drug Safety Update 2020;13(8):1.
Contributors DTB Team.
Provenance and peer review Commissioned; internally peer reviewed.